Clinical Research Directory

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged ≥18 years * For females of reproductive potential: use of highly effective contraception for at least 1 month before screening and agreement to use such a method during study participation and for an additional 9 months after the end of the last dose of study medication administration * Female patients including WOCBP must test negative for pregnancy at the time of screening based on a urine or serum pregnancy test. * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with a partner during the study and for 4 months after the last dose of study medication. * Histologically or cytologically confirmed locally advanced or metastatic PDAC that has not been previously treated * Radiographically confirmed measurable (per RECIST 1.1) locally advanced or metastatic PDAC per the National Comprehensive Cancer Network (NCCN) definition. * Inoperable status due to the presence of locally advanced, unresectable disease with or metastases. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Hematological, biochemical, and organ function inclusion criteria: * Absolute neutrophil count (ANC) ≥1500/mm3 without the use of hemopoietic growth factors within 7 days before treatment * Platelet count ≥100,000/mm3. * International normalized ratio (INR) \<1.5 unless the patient is receiving anticoagulation therapy, in which case a therapeutic INR is acceptable. Anticoagulation therapy with low-molecular weight heparin or warfarin, whether medically indicated, is permitted. * Adequate renal function, as evidenced by serum/plasma creatinine level \<1.6 mg/dL Exclusion Criteria: * Pregnancy or lactation * Treatment with another investigational drug or other intervention within 30 days of protocol initiation. * Known hypersensitivity/allergic reaction to any of the components of the therapeutic agents in mGAP or NALIRIFOX. * Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate, and participate in the study or who is likely to interfere with the interpretation of the results. * Unwilling or unable to comply with study procedures and/or study visits. * Uncontrolled, active infection * Histologic diagnosis other than adenocarcinoma. * Medical co-morbidities, that preclude major abdominal surgery